Lucius Pharmaceuticals
Capmatinib Cancer (oncology)
Originator: Tabrecta · Novartis (discovered by Incyte, licensed to Novartis in 2009)
| Brand | Strength | Form |
|---|---|---|
| LuciCapma | 200 mg film-coated tablets (60 tablets per box) | — |
Lorlatinib Cancer (oncology)
Originator: Lorbrena · Pfizer Inc.
| Brand | Strength | Form |
|---|---|---|
| Lucius lorlatinib | not confirmed | — |
Pralsetinib Cancer (oncology)
Originator: Gavreto · Discovered by Blueprint Medicines; co-commercialised with Genentech (Roche) in the US and by Roche ex-US; Blueprint regained global rights (excluding Greater China) in 2023
| Brand | Strength | Form |
|---|---|---|
| LuciPral | 100 mg x 120 capsules | — |
Sotorasib Cancer (oncology)
Originator: Lumakras · Amgen
| Brand | Strength | Form |
|---|---|---|
| LuciSot | 120 mg x 56 tablets | — |
This page is an information resource for healthcare professionals, licensed importers and patients under medical care. It is not medical advice, not a prescription service, and not an offer to sell prescription medicines to the public.
Need a verified quotation?
Send us the molecule, strength, pack size, quantity and destination country. We reply with a batch-traceable quotation, certificates of analysis and shipping documentation.
We supply licensed pharmacies, hospitals, importers and distributors — not direct-to-consumer patients.
